Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Amgen
University of Arizona
Therapeutic Advances in Childhood Leukemia Consortium
Stanford University
Wugen, Inc.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Institute of Hematology & Blood Diseases Hospital, China
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Syndax Pharmaceuticals
Massachusetts General Hospital
Baylor College of Medicine
Xencor, Inc.
BeiGene
OrphAI Therapeutics
Syndax Pharmaceuticals
Kyowa Kirin Co., Ltd.
Amgen
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Canadian Cancer Trials Group
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Columbia University
Weill Medical College of Cornell University
H. Lee Moffitt Cancer Center and Research Institute
BeiGene
BTG International Inc.
UNC Lineberger Comprehensive Cancer Center
Cyclacel Pharmaceuticals, Inc.
Celgene
Memgen, Inc.
Icahn School of Medicine at Mount Sinai
Albert Einstein College of Medicine
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Children's Mercy Hospital Kansas City
Children's Hospital Medical Center, Cincinnati
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Miami
Celgene
Daiichi Sankyo
M.D. Anderson Cancer Center
Baylor College of Medicine